[go: up one dir, main page]

ATE280783T1 - Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis - Google Patents

Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis

Info

Publication number
ATE280783T1
ATE280783T1 AT96939805T AT96939805T ATE280783T1 AT E280783 T1 ATE280783 T1 AT E280783T1 AT 96939805 T AT96939805 T AT 96939805T AT 96939805 T AT96939805 T AT 96939805T AT E280783 T1 ATE280783 T1 AT E280783T1
Authority
AT
Austria
Prior art keywords
psoriasis
antibodies
diagnosis
treatment
monoclonal anti
Prior art date
Application number
AT96939805T
Other languages
English (en)
Inventor
Casimiro Jose Enrique Montero
Dios Fraga Juan
Valladares Josefa Lombardero
La Vibora Langueruela
Rodriguez Rolando Perez
Blazquez Patricia Sierra
Bravo Blanca Rosa Tormo
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Application granted granted Critical
Publication of ATE280783T1 publication Critical patent/ATE280783T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT96939805T 1995-11-17 1996-11-18 Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis ATE280783T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU1995120A CU22584A1 (es) 1995-11-17 1995-11-17 Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
PCT/CU1996/000004 WO1997019111A2 (es) 1995-11-17 1996-11-18 Anticuerpos monoclonales anti-cd6 y sus utilizaciones

Publications (1)

Publication Number Publication Date
ATE280783T1 true ATE280783T1 (de) 2004-11-15

Family

ID=5459401

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96939805T ATE280783T1 (de) 1995-11-17 1996-11-18 Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis

Country Status (15)

Country Link
US (1) US6572857B1 (de)
EP (1) EP0807125B1 (de)
JP (1) JP4113929B2 (de)
KR (1) KR100533854B1 (de)
CN (1) CN1222540C (de)
AT (1) ATE280783T1 (de)
AU (1) AU722882B2 (de)
BR (1) BRPI9607171B1 (de)
CA (1) CA2210751C (de)
CU (1) CU22584A1 (de)
DE (1) DE69633717T2 (de)
DK (1) DK0807125T3 (de)
ES (1) ES2231826T3 (de)
PT (1) PT807125E (de)
WO (1) WO1997019111A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215450A1 (en) * 2000-05-26 2003-11-20 Blake Simon M Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
CU23097A1 (es) * 2002-10-23 2005-11-18 Centro Inmunologia Molecular Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método
WO2004074318A2 (en) 2003-02-24 2004-09-02 Institut Pasteur Secreted chlamydia polypeptides, polynucleotides coding therefor, therapeutic and diagnostic uses thereof.
EP2119453B1 (de) 2006-12-26 2015-05-20 Centro de Inmunolgía Molecular Pharmazeutische zusammensetzung, die apoptose in tumorzellen auslösen kann, zur diagnose und behandlung von b-chronischer lymphozytischer leukämie
ES2785043T3 (es) * 2006-12-26 2020-10-05 Ct Inmunologia Molecular Composición farmacéutica, que comprende un anticuerpo monoclonal anti-cd6 usado en el diagnóstico y tratamiento de la artritis reumatoide
WO2009089062A2 (en) 2008-01-11 2009-07-16 Synovex Corporation Cadherin-11 ecl domain antagonists for treating inflammatory joint disorders
JP2011513479A (ja) 2008-03-14 2011-04-28 バイオコン・リミテッド モノクローナル抗体、及びその（ｔｈｅｒｏｆ）方法
CN103153331B (zh) * 2010-07-15 2017-03-22 亚德赫伦医疗公司 靶向于钙粘着蛋白‑11的ec1结构域的人源化抗体及相关组合物和方法
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19177059T1 (de) 2010-10-01 2021-10-07 Modernatx, Inc. N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9910039B2 (en) 2011-07-01 2018-03-06 Beckman Coulter, Inc. Regulatory T cells and methods of identifying, obtaining and using to treat immuno-based disorders
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
EP2791160B1 (de) 2011-12-16 2022-03-02 ModernaTX, Inc. Modifizierte mrna zusammensetzungen
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
CA2868393A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
SI2922554T1 (sl) 2012-11-26 2022-06-30 Modernatx, Inc. Terminalno modificirana RNA
FR3000216B1 (fr) * 2012-12-21 2015-02-06 Galderma Res & Dev Utilisation de proteases particulieres pour la detection de trichophytons et de pathologies associees
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
PL3024485T3 (pl) 2013-07-23 2021-06-14 Biocon Limited Zastosowanie partnera wiążącego cd6 i oparty na tym sposób
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
CN105504062B (zh) * 2015-12-25 2019-06-04 百泰生物药业有限公司 一种抗CD6单抗T1h的检测性抗体及应用
PT3529274T (pt) 2016-10-21 2024-06-21 Biocon Ltd Um anticorpo monoclonal e um método de utilização para o tratamento de lúpus
JP7572041B2 (ja) 2018-02-27 2024-10-23 エクイリウム，インコーポレイテッド 重症喘息を処置するための組成物および方法
CN112638478A (zh) 2018-06-29 2021-04-09 希望之城公司 用于治疗某些自身免疫病症的cd6靶向性嵌合抗原受体
WO2020176682A1 (en) 2019-02-26 2020-09-03 Equillium, Inc. Anti-cd6 antibody compositions and methods for treating lupus
WO2021138454A1 (en) 2019-12-30 2021-07-08 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
IL311287A (en) 2021-09-08 2024-05-01 Ct Inmunologia Molecular Use of anti-CD6 monoclonal antibodies in the prevention of damage to cells and organs as a result of a hyper-inflammatory reaction
WO2025096685A1 (en) 2023-10-30 2025-05-08 City Of Hope Methods of making and using regulatory t cells for treatment of autoimmune disorders and cancers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU703694B2 (en) * 1993-11-02 1999-04-01 Bristol-Myers Squibb Company CD6 ligand
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos

Also Published As

Publication number Publication date
CA2210751C (en) 2007-01-30
CN1175957A (zh) 1998-03-11
CA2210751A1 (en) 1997-05-29
MX9705445A (es) 1998-06-30
US6572857B1 (en) 2003-06-03
CU22584A1 (es) 1999-11-03
ES2231826T3 (es) 2005-05-16
PT807125E (pt) 2005-03-31
BR9607171A (pt) 1997-11-11
JPH11506017A (ja) 1999-06-02
EP0807125B1 (de) 2004-10-27
JP4113929B2 (ja) 2008-07-09
DE69633717D1 (de) 2004-12-02
WO1997019111A3 (es) 1998-02-12
EP0807125A2 (de) 1997-11-19
AU7690596A (en) 1997-06-11
AU722882B2 (en) 2000-08-10
DE69633717T2 (de) 2006-02-02
WO1997019111A2 (es) 1997-05-29
KR100533854B1 (ko) 2006-09-20
KR19980701502A (ko) 1998-05-15
DK0807125T3 (da) 2005-03-14
CN1222540C (zh) 2005-10-12
BRPI9607171B1 (pt) 2016-07-19

Similar Documents

Publication Publication Date Title
ATE280783T1 (de) Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis
EP0671920A4 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv-verwandten krankheiten.
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
DE69533040D1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
DE69536017D1 (de) Methoden und zusammensetzungen für die behandlung von glomerulonephritis
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
EP0669836A1 (de) Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma.
DE69822665D1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
ATE348113T1 (de) Rekombinanter anti-cd4 antikörper zur menschlichen behandlung
ATE244018T1 (de) Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
DE69630479D1 (de) Arzneimittel zur Behandlung von entzündlichen Herzkrankheiten
HUP0103573A2 (hu) Trombózis elleni hatóanyag és von Willebrand faktor elleni monoklonális antitest
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
ATE407149T1 (de) Detoxifizierung durch intramuskulär verabreichte f(ab')2 fragmente
DE3854267D1 (de) HIV-spezifische monoklonale Antikörper und Hybridome zu ihrer Herstellung.
FR2804027B1 (fr) Utilisation d'anticorps monoclonaux anti-ferritines dans le traitement de certains cancers
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
DE60020970D1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf-erkrankungen
ATE372349T1 (de) Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen
ATE203680T1 (de) Konjugat zur behandlung von entzündungserkrankungen
DE60208040D1 (de) Anti-ssrp-1 monoklonale antikörper und hybridome zur deren herstellung
DE3779283D1 (de) Zwei-phasen-shampoo zur reinigung, pflege und medizinischen behandlung.
ATE76282T1 (de) Zwei-phasen-shampoo zur reinigung, pflege und medizinischen behandlung.
ATE94759T1 (de) Verwendung von dextransulfat, gegebenenfalls in kombination mit anti-androgenen mitteln zur behandlung des humanen protatakarzinoms.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0807125

Country of ref document: EP